(Q39027480)

8 September 2017

title

Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib (English)

1 reference

8 September 2017

main subject

metastatic breast cancer

1 reference

Galatea Kallergi

3

0 references

Sofia Agelaki

2

object named as

Sofia Agelaki

1 reference

8 September 2017

Antonia Kalykaki

1

1 reference

8 September 2017

Alexandros Xyrafas

4

1 reference

8 September 2017

Dimitris Mavroudis

5

1 reference

8 September 2017

Vassilis Georgoulias

6

1 reference

8 September 2017

publication date

4 February 2014

1 reference

Cancer Chemotherapy and Pharmacology

8 September 2017

published in

1 reference

8 September 2017

volume

73

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

685-693

1 reference

The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Detection and clinical importance of micrometastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Role of epidermal growth factor receptor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2387-Y

10.1007/S00280-014-2387-Y

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference